Fallopian Tube Cancer - Pipeline Review, H2 2013


#172043

143pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, Fallopian Tube Cancer - Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Fallopian Tube Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer. Fallopian Tube Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Fallopian Tube Cancer.
  • A review of the Fallopian Tube Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Fallopian Tube Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Fallopian Tube Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Fallopian Tube Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7

Introduction 8
Global Markets Direct Report Coverage 8
Fallopian Tube Cancer Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Fallopian Tube Cancer 10
Fallopian Tube Cancer Therapeutics under Development by Companies 12
Fallopian Tube Cancer Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Fallopian Tube Cancer Therapeutics Products under Development by Companies 18
Fallopian Tube Cancer Therapeutics Products under Investigation by Universities/Institutes 19
Companies Involved in Fallopian Tube Cancer Therapeutics Development 20
Boehringer Ingelheim GmbH 20
Amgen Inc. 21
AstraZeneca PLC 22
Eli Lilly and Company 23
GlaxoSmithKline plc 24
Daiichi Sankyo Company, Ltd 25
Oxford BioMedica plc 26
Millennium Pharmaceuticals, Inc. 27
Novartis AG 28
Cell Therapeutics, Inc. 29
Incyte Corporation 30
EntreMed, Inc. 31
Marshall Edwards, Inc. 32
Oncolytics Biotech Inc. 33
Synta Pharmaceuticals Corp. 34
Oasmia Pharmaceutical AB 35
Spectrum Pharmaceuticals, Inc. 36
Acceleron Pharma, Inc. 37
TRION Pharma GmbH 38
TetraLogic Pharmaceuticals 39
ImmunoVaccine Technologies Inc. 40
VentiRx Pharmaceuticals, Inc. 41
TRACON Pharmaceuticals, Inc. 42
RECEPTA Biopharma S.A. 43
Fallopian Tube Cancer Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Combination Products 45
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 51
trebananib - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
paclitaxel poliglumex - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ENMD-2076 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
dalantercept - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
elesclomol - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
paclitaxel - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
TroVax - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ramucirumab - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
MEK-162 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
pelareorep - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
idronoxil - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
nintedanib - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
catumaxomab - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
VTX-2337 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
plevitrexed - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
exatecan mesylate - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
TRC-105 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
RebmAb-100 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
EGEN-001 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
OC-DC Vaccine - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
pazopanib hydrochloride - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
INCB-24360 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
NY-ESO-1 Overlapping Peptides Vaccine - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
birinapant - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
ABT-767 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
Globo-H-GM2-sTn-TF-Tn-KLH Conjugate + [QS-21] - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
metformin - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Fallopian Tube Cancer Therapeutics Drug Profile Updates 110
Fallopian Tube Cancer Therapeutics Discontinued Products 136
Fallopian Tube Cancer Therapeutics - Dormant Products 137
Fallopian Tube Cancer Product Development Milestones 138
Featured News & Press Releases 138
Oct 08, 2012: Scottish Medicines Consortium Rejects Roches Avastin For Ovarian Cancer 138
Sep 20, 2012: Roches Avastin Obtains Positive Opinion From CHMP To Treat Various Cancers 138
May 14, 2012: Lilly Oncology To Present Clinical Data Of Ramucirumab At ASCO 2012 139
Nov 01, 2010: Synta Announces Gynecologic Oncology Group To Initiate Phase II Clinical Trial Of Elesclomol For Treatment Of Ovarian Cancer 140
Sep 02, 2010: Oncolytics Biotech Announces Phase II Ovarian Cancer Study To Be Conducted By Gynecologic Oncology Group 141

Appendix 142
Methodology 142
Coverage 142
Secondary Research 142
Primary Research 142
Expert Panel Validation 142
Contact Us 143
Disclaimer 143

Number of Products Under Development for Fallopian Tube Cancer, H2 2013 10
Products under Development for Fallopian Tube Cancer Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 13
Number of Products under Investigation by Universities/Institutes, H2 2013 14
Comparative Analysis by Late Stage Development, H2 2013 15
Comparative Analysis by Mid Clinical Stage Development, H2 2013 16
Comparative Analysis by Early Clinical Stage Development, H2 2013 17
Products under Development by Companies, H2 2013 18
Products under Investigation by Universities/Institutes, H2 2013 19
Boehringer Ingelheim GmbH, H2 2013 20
Amgen Inc., H2 2013 21
AstraZeneca PLC, H2 2013 22
Eli Lilly and Company, H2 2013 23
GlaxoSmithKline plc, H2 2013 24
Daiichi Sankyo Company, Ltd, H2 2013 25
Oxford BioMedica plc, H2 2013 26
Novartis AG, H2 2013 28
Cell Therapeutics, Inc., H2 2013 29
Incyte Corporation, H2 2013 30
EntreMed, Inc., H2 2013 31
Marshall Edwards, Inc., H2 2013 32
Oncolytics Biotech Inc., H2 2013 33
Synta Pharmaceuticals Corp., H2 2013 34
Oasmia Pharmaceutical AB, H2 2013 35
Acceleron Pharma, Inc., H2 2013 37
TRION Pharma GmbH, H2 2013 38
TetraLogic Pharmaceuticals, H2 2013 39
VentiRx Pharmaceuticals, Inc., H2 2013 41
TRACON Pharmaceuticals, Inc., H2 2013 42
RECEPTA Biopharma S.A., H2 2013 43
Assessment by Monotherapy Products, H2 2013 44
Assessment by Combination Products, H2 2013 45
Assessment by Stage and Route of Administration, H2 2013 47
Assessment by Stage and Molecule Type, H2 2013 50
Fallopian Tube Cancer Therapeutics Drug Profile Updates 110
Fallopian Tube Cancer Therapeutics Discontinued Products 136
Fallopian Tube Cancer Therapeutics Dormant Products 137
Number of Products under Development for Fallopian Tube Cancer, H2 2013 10
Products under Development for Fallopian Tube Cancer Comparative Analysis, H2 2013 11
Products under Development by Companies, H2 2013 12
Products under Investigation by Universities/Institutes, H2 2013 14
Late Stage Products, H2 2013 15
Mid Clinical Stage Products, H2 2013 16
Early Clinical Stage Products, H2 2013 17
Assessment by Monotherapy Products, H2 2013 44
Assessment by Combination Products, H2 2013 45
Assessment by Route of Administration, H2 2013 46
Assessment by Stage and Route of Administration, H2 2013 47
Assessment by Molecule Type, H2 2013 48
Assessment by Stage and Molecule Type, H2 2013 49